GlassScriptPhysician profile
Zachary Daniel Smith
NPI 1437537024
$5,721.58
in general payments reported to CMS, 2019-2025
30 companies · $1,702 in 2025
The $1,702 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.36 · 2021: $393 · 2022: $1,240 · 2023: $1,105 · 2024: $1,208 · 2025: $1,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,992 · Education: $22.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,992.00 |
| Education | $22.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,635.25 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $843.13 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Aimmune Therapeutics, INC. | $155.91 | 2024-2025 | Zenpep |
| Genzyme Corporation | $143.90 | 2023-2025 | |
| Ardelyx, INC. | $142.86 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $142.07 | 2021-2024 | Dificid |
| Celgene Corporation | $119.62 | 2022-2024 | Zeposia |
| Daiichi Sankyo INC. | $111.63 | 2022-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $109.79 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $109.25 | 2023-2025 | Vegzelma, Yuflyma |
| Janssen Biotech, INC. | $106.23 | 2024-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $103.95 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.18 | 2021-2024 | Trulance |
| Pfizer INC. | $95.83 | 2024-2025 | |
| Lilly USA, LLC | $93.37 | 2024-2025 | Omvoh |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $85.11 | 2023-2025 | |
| Covidien LP | $74.36 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $70.39 | 2025 | Iqirvo |
| Novo Nordisk INC | $58.90 | 2025 | Wegovy |
| Pharmacosmos Therapeutics INC. | $57.35 | 2023 | Monoferric |
| Amgen INC. | $53.81 | 2023-2025 | Avsola, Amjevita, Uplizna |
| Nestle Healthcare Nutrition INC. | $52.72 | 2021-2023 | |
| Madrigal Pharmaceuticals | $51.00 | 2025 | Rezdiffra |
| Qol Medical, LLC | $48.87 | 2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $48.27 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $26.03 | 2022-2023 | Sutab |
| Medtronic, INC. | $24.76 | 2025 | Interstim |
| Fresenius Kabi USA, LLC | $21.02 | 2023 | Idacio |
| Ironwood Pharmaceuticals, INC | $18.12 | 2024 | |
| Sandoz INC. | $16.90 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.